You are in: eMedicine Specialties > Dermatology > FUNGAL INFECTIONS PiedraArticle Last Updated: Apr 30, 2008AUTHOR AND EDITOR INFORMATIONAuthor: Robert A Schwartz, MD, MPH, Professor and Head of Dermatology, Professor of Medicine, Professor of Pediatrics, Professor of Pathology, Professor of Preventive Medicine and Community Health, UMDNJ-New Jersey Medical School Robert A Schwartz is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Physicians, and Sigma Xi Coauthor(s): Rachel Altman, MD, Staff Physician, Department of Dermatology, UMDNJ-New Jersey Medical School Editors: Neil Shear, MD, Professor and Chief of Dermatology, Professor of Medicine, Pediatrics and Pharmacology, University of Toronto Faculty of Medicine; Head of Dermatology, Sunnybrook Women's College Health Sciences Center and Women's College Hospital, Canada; Michael J Wells, MD, Associate Professor, Department of Dermatology, Texas Tech University Health Sciences Center; Christen M Mowad, MD, Associate Professor, Department of Dermatology, Geisinger Medical Center; Glen H Crawford, MD, Assistant Clinical Professor, Department of Dermatology, University of Pennsylvania School of Medicine; Chief, Division of Dermatology, The Pennsylvania Hospital; Dirk M Elston, MD, Director, Department of Dermatology, Geisinger Medical Center Author and Editor Disclosure Synonyms and related keywords: black piedra, white piedra, trichosporosis, asymptomatic superficial fungal infection of the hair shaft, Pleurococcus beigelii, P beigelii, Trichosporon beigelii, T beigelii, Piedraia hortae, P hortae, Trichosporon cutaneum, T cutaneum INTRODUCTIONBackgroundPiedra, which means "stone" in Spanish, is an asymptomatic superficial fungal infection of the hair shaft. In 1865, Beigel1 first described piedra in The Human Hair: Its Structure, Growth, Diseases, and Their Treatment; although, he may have been describing Aspergillus infection. In 1911, Horta classified piedra into 2 types. The first is black piedra, which is caused by Piedraia hortae. The second is white piedra. The etiological agents of white piedra, originally named Pleurococcus beigelii and later Trichosporon beigelii, are now called Trichosporon asahii and 5 other species: Trichosporon ovoides, Trichosporon inkin, Trichosporon mucoides, Trichosporon asteroides, and Trichosporon cutaneum. These 6 organisms are all causative agents of white piedra. T asahii is considered most closely linked to white piedra, although some authorities believe T ovoides is the main agent of white piedra of the scalp. Use of the term T beigelli should be avoided.2 The 2 types of piedra occur in different climatic conditions. Black piedra is most common in the tropical regions of the world that have high temperatures and humidity. For example, black piedra may occur in many central South American countries, including Brazil, as well as in Southeast Asia. It is rare in the United States. White piedra is more common in temperate and semitropical climates, such as those in South America, Asia, Europe, Japan, and parts of the southern United States. In addition, the 2 types of piedra affect the hair in different body locations. Black piedra usually affects scalp hair, whereas white piedra more commonly affects pubic hair, axillary hair, beards, mustaches, and eyebrows and/or eyelashes. However, in Brazil, white piedra is reported to affect scalp hair most commonly.3 White piedra affects horses and monkeys, in addition to humans. Black piedra occurs in monkeys and humans. Both types of piedra ultimately may lead to hair breaking because the shaft is weakened by cuticular penetration. In patients who are immunocompromised, dissemination of T asahii can occur, causing purpuric or necrotic cutaneous papules and nodules. Culture or biopsy samples from skin lesions may reveal the causative organism. Related organisms may be found on animal hair, in soil, or in stagnant water.4 Gonzalez et al documented outbreaks of clinical mastitis caused by T asahii in dairy herds. This intramammary infection of affected cows causes hyperthermia, swelling of the udder, and decreased milk production or agalactia; this infection can be fatal in cows.5 PathophysiologyThe environment and typical skin flora are the 2 main sources of infectious agents that cause piedra. The source of infection in black piedra, P hortae, appears to be in the soil; however, infection also has been traced to organisms in stagnant water and crops.6, 7 The source of infection for white piedra, typically T asahii, can be present in the soil, air, water, vegetable matter, or sputum or on body surfaces.4 However, the mode of infection in man is not clear. White piedra has been described in horses, monkeys, and dogs.8 Trichosporon species may also be causative agents of onychomycosis. A German study showed that among yeasts, they represented 10% of such infections.9 In addition, T asahii fungemia may develop in clinically deteriorated patients with or without an underlying hematological malignancy,10 as in a neutropenic patient with acute leukemia.11 FrequencyUnited StatesWhite piedra is quite common in parts of the southern United States and less so elsewhere in America. However, it may be emerging as a commonly seen hair and scalp infection in the northeastern United States.12 InternationalBlack piedra is most common in tropical regions such as South America, Far East, and the Pacific Islands. At one time, black piedra reportedly was endemic in Brazilian Indians living in the northern area of midwestern Brazil.13 This trend may have been linked to the Brazilian Indians' cultural use of plant oils in their hair. White piedra is more common in temperate and semitropical climates, such as those in Asia, Europe, Japan, and parts of the southern United States. Mortality/MorbidityCosmetic morbidity occurs because piedra may affect the patient's body image; the hair shaft may break and/or the patient may need to shave the affected hair. RaceIn the United States, the occurrence of piedra may be higher in blacks than in whites; however, many cases may be underreported because nodules of piedra may be inconspicuous.14 SexBoth sexes are affected equally. Black piedra initially was believed to be more common in men than in women; however, a study among the Zoro Indians of Brazil revealed no significant differences between the sexes.6 In another study among Brazilian Indians, black piedra affected both sexes equally.13 Twenty-three cases of scalp white piedra were described in Brazil, with a high incidence in women (87%) and preschool children aged 2-6 years (74%).8 AgeIndividuals of all ages are affected. In a study of Brazilian Indians, persons of all ages were affected, from young children to adults older than 70 years, although black piedra infected young adults most frequently.13 In one series of 23 Brazilian patients with scalp white piedra, a high incidence was found in preschool children aged 2-6 years (74%).8 CLINICALHistoryWhite piedra shows irregular, white, cream-colored, or brown soft nodules or gelatinous sheaths along the hair shaft. They can be easily detached from the hair shaft. White piedra is found in the hair of the beard, moustache, genitals, and axilla. Eyebrow and eyelash involvement can also be present, while on the scalp, white piedra appears to be less common.
Physical
CausesT asahii can cause white piedra and occasionally an onychomycosis.20, 21 The genus Trichosporon Behrend consists of 6 human pathogenic species: T asahii, T mucoides, T ovoides, T asteroides, T cutaneum, and T inkin and all of which belong to the class Basidiomycetes.8, 22 These species are the causative agents of piedra and other superficial infections as well as mucosa-associated systemic mycosis.22 DIFFERENTIALSLice Monilethrix Tinea Capitis Trichomycosis Axillaris Trichorrhexis Nodosa
|
| Drug Name | Clotrimazole 1% (Lotrimin, Mycelex) |
|---|---|
| Description | Often a first-line drug used in the treatment of tinea cruris. Available by prescription only. Cream, solution or spray, and lotion forms are available. |
| Adult Dose | Apply topically to affected areas bid for 4 wk or until condition resolves |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | None reported |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Not for treatment of systemic fungal infections; avoid contact with eyes; if irritation or sensitivity develops, discontinue and initiate appropriate therapy |
| Drug Name | Miconazole 2% (Micatin, Monistat-Derm, Femizole-7, Lotrimin) |
|---|---|
| Description | Imidazole used in the treatment of tinea cruris. Available over the counter. Cream, solution or spray, lotion, and powder forms are available. |
| Adult Dose | Apply topically to affected areas bid for 4 wk or until condition resolves |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | None reported |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Discontinue if sensitivity or chemical irritation occurs; for external use only; avoid contact with eyes |
| Drug Name | Ketoconazole 2% cream (Nizoral cream) |
|---|---|
| Description | Imidazole broad-spectrum antifungal agent; inhibits synthesis of ergosterol, causing cellular components to leak, resulting in fungal cell death. |
| Adult Dose | Apply topically to affected areas qd for 2-4 wk or until condition resolves |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | None reported |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Discontinue if sensitivity or irritation develops; for external use only; avoid contact with eyes |
| Drug Name | Econazole 1% (Spectazole) |
|---|---|
| Description | Effective in cutaneous infections. Interferes with RNA and protein synthesis and metabolism. Disrupts fungal cell-wall permeability, causing fungal cell death. |
| Adult Dose | Apply topically to affected areas qd until condition resolves |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | None reported |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Discontinue if sensitivity or irritation develops; for external use only; avoid contact with eyes |
| Drug Name | Terbinafine (Lamisil) |
|---|---|
| Description | Allylamine derivative that inhibits squalene epoxidase, a key enzyme in sterol biosynthesis in fungi. This inhibition results in a deficiency in ergosterol within the fungal cell wall that causes fungal cell death. Terbinafine is available by prescription only. Some clinicians reserve the use of this drug for more widespread and/or resistant infections because of its broad coverage and cost. This medication is effective and well tolerated in children. |
| Adult Dose | White piedra: Apply topically to the affected area qd for 2 wk or until condition resolves Black piedra: 250 mg/d PO; not to exceed 12 wk |
| Pediatric Dose | Topical: Administer as in adults Oral: 12-20 kg: 62.5 mg/d 20-40 kg: 125 mg/d >40 kg: 250 mg/d Treatment duration as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | Possible interactions with drugs metabolized by the CYP-450 (P-450) 2D6 enzyme (eg, tricyclic antidepressants, propranolol, theophylline); may decrease cyclosporin levels; rifampin increases clearance; cimetidine may increase toxicity |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Reduce oral dose in renal insufficiency; discontinue if hepatobiliary dysfunction, neutropenia, Stevens-Johnson syndrome, or changes in ocular lens or retina develop; discontinue topical use if chemical irritation develops Monitor patient response and adjust caffeine dosage during combined treatment with terbinafine; observe for signs of caffeine toxicity (headache, agitation, insomnia, diuresis, fever) |
| Drug Name | Oxiconazole 1% (Oxistat) |
|---|---|
| Description | Damages fungal cell wall membrane by inhibiting biosynthesis of ergosterol. Increases membrane permeability, causing nutrients to leak out, resulting in fungal cell death. |
| Adult Dose | Apply to affected area qd/bid until condition resolves |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | None reported |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Discontinue if sensitivity or chemical irritation occurs; for external use only; avoid contact with eyes |
| Drug Name | Sulconazole 1% (Exelderm) |
|---|---|
| Description | Broad-spectrum imidazole derivative with antifungal and antiyeast activity. For topical use. Inhibits growth of common pathogenic dermatophytes. |
| Adult Dose | Apply to affected areas qd/bid for 2-4 wk or until condition resolves |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity |
| Interactions | None reported |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Discontinue if sensitivity or chemical irritation occurs; for external use only; avoid contact with eyes |
| Drug Name | Itraconazole (Sporanox) |
|---|---|
| Description | Fungistatic activity. Synthetic triazole antifungal agent that slows fungal cell growth by inhibiting cytochrome P-450–dependent synthesis of ergosterol, a vital component of fungal cell membranes. Absorption improved with food and in presence of normal gastric acidity. Patients should be cautioned against ingesting grapefruit juice while on itraconazole therapy (decreased oral bioavailability of itraconazole). Discontinue if sensitivity or chemical irritation occurs; for external use only; avoid contact with eyes. |
| Adult Dose | 100 mg PO qd until culture negativity achieved |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; congestive heart failure or history of congestive heart failure (itraconazole cap for treatment of superficial fungal infections), concurrent administration with cisapride, midazolam, triazolam, lovastatin, dofetilide, pimozide, levacetylmethadol (levomethadyl), quinidine, lovastatin, simvastatin, and ergot alkaloids metabolized by CYP3A4 (eg, dihydroergotamine, ergometrine [ergonovine], ergotamine, methylergometrine [methylergonovine]); women contemplating pregnancy |
| Interactions | As CYP3A4 inhibitor (P450 metabolism), many drugs have interactions when coadministered with itraconazole; avoid alcohol use because disulfiramlike reaction may occur; antacids may reduce absorption; edema may occur with coadministration of calcium channel blockers (eg, amlodipine, nifedipine); hypoglycemia may occur with sulfonylureas; high doses may increase tacrolimus and cyclosporine plasma concentrations; rhabdomyolysis may occur with coadministration of HMG-CoA reductase inhibitors (eg, lovastatin, simvastatin); coadministration with cisapride can cause cardiac rhythm abnormalities and death; may increase digoxin levels; coadministration may increase plasma levels of midazolam or triazolam; phenytoin and rifampin may reduce levels (phenytoin metabolism may be altered) Reduced itraconazole plasma concentrations reported with concurrent use of H2 antagonist and aluminum-, calcium-, or magnesium-containing products (administer aluminum-, calcium-, or magnesium-containing products at least 1 h before or 2 h after itraconazole cap); enhances anticoagulant effects of coumarinlike drugs |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Caution in hepatic insufficiencies; adverse effects include headache, nausea, vomiting, reversible elevation of liver enzyme levels, hepatotoxicity, hallucinations, hypokalemia, heart failure, edema, congestive heart failure, and neutropenic disorder; oral solution and oral capsules not to be used interchangeably; injection not for use in patients with CrCl <30 mL/min, and use with caution in patients with CrCl of 30-80 mL/min |
| Drug Name | Ciclopirox (Loprox) |
|---|---|
| Description | Interferes with DNA, RNA, and protein synthesis by inhibiting the transport of essential elements in fungal cells. |
| Adult Dose | Massage into affected area bid until condition resolves |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | None reported |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Avoid contact with eyes and other internal routes |
| Drug Name | Naftifine (Naftin) |
|---|---|
| Description | Indicated for the treatment of tinea corporis, tinea cruris, and tinea pedis. Broad-spectrum antifungal agent that appears to interfere with sterol biosynthesis by inhibiting the enzyme squalene 2,3-epoxidase. This inhibition results in decreased amounts of sterols, causing cell death. If no clinical improvement occurs after 4 wk of treatment, reevaluate patient. |
| Adult Dose | Gently and sparingly massage the cream or gel into affected area and surrounding skin qd/bid for 2-4 wk or until condition resolves |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | None reported |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Discontinue use if sensitivity or chemical irritation occurs; for external use only; avoid contact with eyes |
These agents may be effective in treating white piedra.
| Drug Name | Selenium sulfide 1-2.5% lotion (Exsel, Selsun) |
|---|---|
| Description | Blocks enzymes involved in growth of epithelial tissue. |
| Adult Dose | Massage for 5-10 min into wet hair, wait for 2-3 min, then rinse; repeat application and rinse; wash hands after treatment; qd until resolved |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | None reported |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | To avoid systemic toxicity, do not use in broken or open skin; avoid use in very young children |
| Drug Name | Carbol-fuchsin (Castellani Paint) |
|---|---|
| Description | First-aid antiseptic and drying agent. Active ingredient is phenol 1.5%. Inactive ingredients are water, SD alcohol 40B (13%), resorcinol, acetone, and basic fuchsin. |
| Adult Dose | Spray or apply to affected area qd/bid |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | None reported |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Avoid contact with clothing; stain slowly wears off; not for application on eroded skin, or large areas; infants may be more sensitive than adults to phenol component |
| Drug Name | Chlorhexidine (Hibiclens, PerioGard) |
|---|---|
| Description | Effective, relatively safe, and reliable topical antiseptic. A polybiguanide with bactericidal activity; usually is supplied as a gluconate salt. At physiologic pH, the salt dissociates to a cation that binds to bacterial cell walls. |
| Adult Dose | Rinse affected area with water, apply sufficient amount to cover affected area, wash gently, then rinse |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | None reported |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Corneal damage may occur; skin irritation, ototoxicity resulting in deafness (when used around the ear), phototoxicity, and/or allergic reactions rare when used to clean superficial wounds (does not cause additional tissue injury or delay healing) |
| Drug Name | Pyrithione zinc (DHS Zinc, Zincon, Head & Shoulders) |
|---|---|
| Description | Cytostatic agent that reduces cell turnover rate. Strongly binds to hair and external skin layers. |
| Adult Dose | Apply shampoo and rinse; use qd until condition resolves; use as with selenium sulfide |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | None reported |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | For external use only; do not apply to eyes |
Article Last Updated: Apr 30, 2008